AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 289: H48-H56, 2005. First published March 4, 2005; doi:10.1152/ajpheart.01159.2004
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/1/H48    most recent
01159.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knudson, J. D.
Right arrow Articles by Tune, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knudson, J. D.
Right arrow Articles by Tune, J. D.

Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction

Jarrod D. Knudson,1 Ü. Deniz Dincer,1 Cuihua Zhang,1,2 Albert N. Swafford, Jr.,1 Ryoji Koshida,1 Andrea Picchi,1,2 Marta Focardi,1 Gregory M. Dick,1 and Johnathan D. Tune1

1Department of Physiology and 2Departments of Surgery and Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, Louisiana

Submitted 17 November 2004 ; accepted in final form 1 March 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Obesity is associated with marked increases in plasma leptin concentration, and hyperleptinemia is an independent risk factor for coronary artery disease. As a result, the purpose of this investigation was to test the following hypotheses: 1) leptin receptors are expressed in coronary endothelial cells; and 2) hyperleptinemia induces coronary endothelial dysfunction. RT-PCR analysis revealed that the leptin receptor gene is expressed in canine coronary arteries and human coronary endothelium. Furthermore, immunocytochemistry demonstrated that the long-form leptin receptor protein (ObRb) is present in human coronary endothelium. The functional effects of leptin were determined using pressurized coronary arterioles (<130 µm) isolated from Wistar rats, Zucker rats, and mongrel dogs. Leptin induced pharmacological vasodilation that was abolished by denudation and the nitric oxide synthase inhibitor N{omega}-nitro-L-arginine methyl ester and was absent in obese Zucker rats. Intracoronary leptin dose-response experiments were conducted in anesthetized dogs. Normal and obese concentrations of leptin (0.1–3.0 µg/min ic) did not significantly change coronary blood flow or myocardial oxygen consumption; however, obese concentrations of leptin significantly attenuated the dilation to graded intracoronary doses of acetylcholine (0.3–30.0 µg/min). Additional experiments were performed in canine coronary rings, and relaxation to acetylcholine (6.25 nmol/l-6.25 µmol/l) was significantly attenuated by obese concentrations of leptin (625 pmol/l) but not by physiological concentrations of leptin (250 pmol/l). The major findings of this investigation were as follows: 1) the ObRb is present in coronary arteries and coupled to pharmacological, nitric oxide-dependent vasodilation; and 2) hyperleptinemia produces significant coronary endothelial dysfunction.

coronary circulation; endothelium; microcirculation; metabolic syndrome; obesity

LEPTIN, THE PRODUCT OF THE OBESITY GENE, is a 16-kDa protein adipokine first implicated in the regulation of metabolism and food intake (54). Since its discovery, leptin has been shown to exert a myriad of effects in many tissues, including vasomotor effects at various peripheral targets (29, 53). However, there is conflict over the vasoactive properties of leptin, and, as a result, its precise role in vascular function has remained elusive. For example, some studies in various noncoronary vascular beds indicate that leptin is a nitric oxide-dependent vasodilator (20, 26, 51), whereas others hold that it exerts nitric oxide-independent vasodilation (33). However, these vascular effects were primarily observed at high concentrations of leptin. Additionally, many studies have shown that leptin increases peripheral vascular resistance, which is logical, based on the abundance of studies that link hyperleptinemia (elevated plasma leptin concentration) to increases in sympathetic nervous activity (6, 10, 13–15, 34, 41, 42).

Plasma leptin concentration positively correlates with adiposity (8), and hyperleptinemia is an independent risk factor for coronary artery disease (37) and a strong predictor of acute myocardial infarction (43). Additionally, leptin has been implicated in many atherogenic processes common to the pathogenesis of cardiovascular disease, including promotion of platelet aggregation and thrombosis (5, 22, 23); production of inflammatory cytokines, e.g., TNF-{alpha}, IL-6, and IL-12 (27); promotion of neointimal growth in mice (39); stimulation of mitochondrial superoxide production in aortic endothelial cells (52); and calcification of vascular smooth muscle cells (35). Interestingly, recent reports have demonstrated that leptin possesses cytokine-like properties and that elevated plasma leptin levels occur concomitantly with elevated IL-6 and C-reactive protein in human obesity, the metabolic syndrome, and non-insulin-dependent diabetes mellitus (25, 28, 32). As a result, hyperleptinemia could contribute to obesity-related coronary endothelial dysfunction; however, little is known about the effects of leptin on the coronary circulation. In fact, only one study has addressed the direct effects of leptin on the coronary circulation. This study, by Matsuda et al. (30), suggests that leptin exerts nitric oxide-independent coronary vasodilation in humans; however, the subjects studied were undergoing cardiac catheterization for angina, and no data are available for normal human or animal subjects.

Because obesity is pandemic in Western society (12) and hyperleptinemia is essentially universal in the obese population, it is important that the mechanisms by which leptin affects the coronary vasculature be delineated. As a result, the aim of this investigation was to test the following hypotheses: 1) the leptin receptor gene (db) is expressed in coronary endothelial cells, and signaling-competent receptors are present; 2) leptin induces nitric oxide-mediated vasodilation in isolated coronary arterioles and anesthetized, open-chest dogs, primarily at high, pharmacological concentrations; and 3) hyperleptinemia (plasma concentrations similar to those observed in obese humans) causes coronary endothelial dysfunction. We tested these hypotheses by using human coronary artery endothelial cells; coronary arterioles isolated from rats and dogs; canine epicardial coronary rings; and open-chest, anesthetized dogs.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell culture. Human coronary artery endothelial cells (HCAEC) were purchased from Cambrex Bio Science and cultured using Clonetics EGM-2 MV BulletKit [basal medium, human EGF, hydrocortisone, gentamicin-ampicillin (GA-1000), FBS, VEGF, human FGF-B, R3-EGF-1, and ascorbic acid].

Reverse transcriptase polymerase chain reaction. Total RNA was isolated from HCAEC using RNeasy Protect Mini and Rnase-Free Dnase kits (Qiagen) (n = 4, sets of HCAEC). Total RNA was eluted in diethylpyrocarbonate-treated water (pH 7.5). RNA concentration and quality were determined spectrophotometrically. RNA was reverse transcribed using Improm II RT-PCR kit (Promega). Primers, synthesized by Invitrogen, were designed using the human leptin receptor cDNA sequence (accession number U66497). Forward and reverse primer sequences were 5'-AGGACGAAAGCCAGAGACAA-3' (3050–3069) and 5'-AAATGCCTGGGCCTCTATCT-3' (3234–3215), respectively. PCR was performed using Taq DNA polymerase kit (Promega). PCR product (expected length = 185 bp) was electrophoresed on a 1% agarose gel, visualized using ethidium bromide stain, extracted from PCR reaction using QIAquick PCR Purification Kit (Qiagen), and sequenced by the Louisiana State University Health Sciences Center Genetics Department Core. {beta}-Actin was amplified in all PCR and served as an internal reference.

Following the in vivo coronary blood flow studies (described below), we excised and immediately immersed the dog hearts in cold (4°C) lactated Ringer solution (Baxter). Left circumflex coronary arteries were quickly and cleanly dissected from the epicardial surface of the heart, flash frozen in liquid nitrogen, and stored at –80°C. Total RNA was isolated from the arteries using a SV Total RNA Isolation system (Promega). After isolation, RNA samples were dissolved in nuclease-free water (pH 7.5), and RNA concentration and quality were determined spectrophotometrically. RNA samples were used as templates for the synthesis of first-strand cDNAs using an ImProm-II Reverse Transcriptase kit (Promega). Primers, synthesized by Invitrogen, were designed using the Canis familiaris long-form leptin receptor (ObRb) cDNA sequence (accession number AY753649). Forward and reverse primer sequences were 5'-ATCCGTGATCAGCACAACAG-3' (158–177 bp) and 5'-AATGGAAGGTGTGGCAAAAT-3' (453–434 bp), respectively. PCR was performed using Taq DNA polymerase kit (Promega). Reaction conditions were as follows: 2.8 µl of 25 mM MgCl for 50-µl reaction volumes; and amplification and 45-s denaturation (95°C) followed by 45-s annealing (55°C) and 2-min extension (72°C), repeated for a total of 37 cycles. {beta}-Actin was amplified in all PCR reactions and served as an internal reference. ObRb PCR product (expected length = 296 bp) was electrophoresed on a 1% agarose gel and visualized using ethidium bromide stain.

Immunocytochemistry. Glass coverslips were sterilized with ethanol and placed into six-well tissue culture plates. Plates were seeded with HCAEC overnight. Cells were fixed with cold methanol (–20°C) and blocked with 5% bovine serum albumin in blocking buffer containing (mmol/l) 25 HEPES, 10 EGTA, 60 PIPES, and 2 MgCl2 (pH 6.9). Sets of fixed cells (n = 5) were incubated overnight at 4°C with rabbit anti-human cell surface-specific ObRb antibody (Linco Research) in blocking buffer and then for 2 h at 25°C with fluorescein (FITC)-conjugated goat anti-rabbit IgG Fc (Jackson Laboratories). Coverslips were washed, dried, and mounted on glass slides. Cells were photographed using a Nikon Eclipse TE2000-U fluorescent microscope with digital imaging system (Sutter Instrument).

Functional assessment of isolated coronary arterioles. This investigation was approved by the Institutional Animal Care and Use Committee in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996).

Mongrel dogs (n = 7), Wistar rats (n = 6), lean Zucker rats (n = 3), and obese Zucker rats (n = 4) were anesthetized with pentobarbital sodium (dogs, 30 mg/kg iv; rats, 65 mg/kg ip; Abbott Laboratories). Hearts were excised and immediately immersed in cold (4°C) lactated Ringer solution. Epicardial coronary arterioles (60–130 µm in situ internal diameter and 0.6–1.0 mm in length without branches) were dissected out as previously described (18, 24). Arterioles were cannulated with glass micropipettes, pressurized to 60 cmH2O, and bathed in physiological salt solution (PSS) containing 1% bovine serum albumin (pH 7.4, 37°C). Arterioles developed spontaneous (myogenic) basal tone, and concentration-diameter relationships were assessed for leptin (10 pmol/l–10 µmol/l, Sigma). Endothelin-1 (1 nmol/l, Sigma) was administered to assess the viability of selected dog arterioles (n = 2) that failed to develop spontaneous, myogenic tone. These microvessels developed and maintained tone similar to that developed spontaneously in other microvessels. Furthermore, after washing (30 min) was completed, relaxation to leptin was unchanged by endothelin-1 administration. Arterioles from dogs (n = 3) were denuded with intraluminally administered 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (0.4%, zwitterionic detergent, Bio-Rad) dissolved in albumin-PSS. Microvessels were then washed with intraluminally administered albumin-PSS for 5 min, and the leptin concentration response was repeated. Also, arterioles (dogs, n = 4; Wistar rats, n = 4) were treated with nitric oxide synthase (NOS) inhibitor N{omega}-nitro-L-arginine methyl ester (L-NAME) (10 µmol/l for 30 min, Sigma), and the leptin concentration-response protocol was repeated. This concentration and duration of L-NAME treatment have previously been shown to be efficacious and specific for NOS inhibition (16–18, 44). At the end of each experiment, the vessel was relaxed with 100 µmol/l sodium nitroprusside to obtain its maximum diameter. All diameter changes in response to agonists were normalized to the dilation response to 100 µmol/l sodium nitroprusside and expressed as a percentage of maximal dilation.

In vivo coronary dose-response experiments. Mongrel dogs (n = 24) were sedated with morphine (Baxter, 3 mg/kg sc), anesthetized with {alpha}-chloralose (100 mg/kg iv, Sigma), and ventilated with room air that was supplemented with oxygen. The left anterior descending coronary artery (LAD) was cannulated and perfused with an extracorporeal circuit as previously described (48). Briefly, the left femoral artery was catheterized to feed a servo-controlled peristaltic-pump circuit used to artificially perfuse the LAD. Coronary perfusion pressure was held constant (100 mmHg) throughout the experimental protocol, and coronary blood flow was measured with an inline Doppler transit-time flow probe (Transonic Systems). Consequently, changes in coronary blood flow reflect changes in coronary microvascular resistance.

After a 20-min recovery period, leptin (0.1–30.0 µg/min) was infused into the coronary perfusion line (n = 9 dogs). Each leptin dose was infused for ~3 min at constant coronary perfusion pressure of 100 mmHg, and data were recorded when coronary blood flow was stable. Arterial and coronary venous blood samples were drawn during steady-state coronary flow at each leptin dose to determine myocardial oxygen consumption (n = 5 dogs). Additional dogs (n = 3) were pretreated with the ganglionic blocker hexamethonium (5 mg/kg iv, Sigma), and the leptin dose-response protocol was performed as described above.

To determine the effects of obese hyperleptinemia on endothelium-dependent and -independent coronary vasodilation, acetylcholine (0.3–30.0 µg/min ic, Sigma) and sodium nitroprusside (1.0–100.0 µg/min ic, Sigma) dose-response experiments were conducted in open-chest dogs (acetylcholine, n = 5; sodium nitroprusside, n = 5) that were anesthetized and instrumented as described above. Each acetylcholine and sodium nitroprusside dose was infused for 2–3 min, and data were recorded when coronary blood flow was stable. After a 10-min recovery period, a continuous intracoronary infusion of leptin (3.0 µg/min) was started. This dose of leptin was chosen to maintain coronary plasma leptin concentration within the obese range. Ten minutes later, the same dose-response protocols were repeated with simultaneous leptin infusion. Additionally, time-control experiments were performed (n = 2 dogs), and there was no tachyphylaxis to acetylcholine.

Functional assessment of isolated epicardial coronary rings. Because coronary artery disease primarily occurs in large coronary vessels, we further tested the hypothesis that obese hyperleptinemia induces coronary endothelial dysfunction in isolated left circumflex coronary rings. Following the in vivo studies described in the previous section, we excised and immediately immersed the dog hearts in cold (4°C) lactated Ringer solution. Left circumflex coronary arteries were dissected from the heart and cleaned of periadventitial fat. Arteries were cut into 5-mm rings (n = 16 rings from 4 dogs) and mounted in organ baths (Kent Scientific) for isometric tension studies. Optimal length was found using KCl (37.5 mmol/l). Passive tension was increased in gram increments until less than a 10% change in active tension developed in response to KCl. Rings were precontracted using U-46619 (625 nmol/l, thromboxane A2 mimetic, BIOMOL). Graded concentrations of acetylcholine (6.25 nmol/l–6.25 µmol/l) were added to the baths in a cumulative manner. Rings were then washed for 30 min. Following washes, leptin (625 pmol/l or ~10 ng/ml) was added to the baths. Ten minutes later, rings were precontracted, and the acetylcholine concentration-response protocol was repeated. Additional experiments, using the protocol delineated above, were performed_using physiological concentrations of leptin (250 pmol/l or ~4 ng/ml, n = 8 rings from 3 dogs). Also, time-control experiments were conducted without leptin administration (n = 8 rings from 2 dogs). Relaxation responses were expressed as percent maximum relaxation. Maximum relaxation is equivalent to the loss of all active tension developed in response to precontraction with U-46619.

Statistical analyses. Data are expressed as means ± SE. Statistical testing detected overall treatment effects. One-way repeated-measures ANOVA was used to test the effects of leptin on coronary blood flow, myocardial oxygen consumption, systemic hemodynamic variables, and changes in arteriolar diameter. Two-way ANOVA was used to compare coronary arteriolar responses to leptin in lean versus obese Zucker rats as well as coronary flow and hemodynamic responses to leptin with and without hexamethonium. Two-way repeated-measures ANOVA was used to test the effect of leptin on changes in arteriolar diameter before and after L-NAME treatment. Two-way repeated-measures ANOVA was also used to test the effect of leptin on acetylcholine- and sodium nitroprusside-mediated coronary vasodilation in vivo and acetylcholine-mediated relaxation of coronary rings in vitro. When significance was found with ANOVA (P < 0.05), a Student-Newman-Keuls post hoc multiple-comparison test was performed to detect differences between treatment levels. Paired t-test was used to compare mean EC50 and mean maximum responses of coronary rings to acetylcholine before and after leptin treatment. Mean arteriolar diameters before and after L-NAME administration or deunudation were also compared using a paired t-test. P < 0.05 was taken to be significant (i.e., {alpha} = 0.05).


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
ObRb is expressed in HCAEC. We performed RT-PCR using RNA isolated from confluent cultures of HCAEC and canine left circumflex coronary arteries. The presence of the expected 185-bp PCR product demonstrates that db is expressed in HCAEC (Fig. 1A). This PCR product was sequenced and compared with GenBank entries using NCBI BLAST software and was most similar to human db. Sequence alignment revealed 96% homology between the 185-bp PCR product and db (accession number U-66497). Additionally, the expected 296-bp PCR product shown in Fig. 1C demonstrates that the ObRb gene is expressed in canine left circumflex coronary arteries. Immunocytochemistry analysis demonstrated the presence of signaling-competent ObRb on HCAEC (Fig. 1B). No immunoreactivity was found in blocked cells incubated only with FITC-conjugated goat anti-rabbit IgG Fc (data not shown).



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 1. Human long-form leptin receptor (ObRb) is expressed in human coronary artery endothelial cells (HCAEC). Leptin receptor gene (db) PCR product (185 bp) was visualized via agarose electrophoresis (A). Immunocytochemistry analysis demonstrates that ObRb is present in coronary endothelium (B). The ObRb gene is also expressed in canine left circumflex coronary arteries [296-bp PCR product (C)].

 
Leptin induces nitric oxide-dependent vasorelaxation in isolated coronary arterioles. Baseline characteristics of isolated coronary arterioles are given in Table 1. The level of basal tone was similar in all treatment groups described below.


View this table:
[in this window]
[in a new window]
  		Table 1. Baseline characteristics of isolated coronary arterioles

 
The vertical lines in Fig. 2 and Fig. 3 denote the range of leptin concentrations that have been reported in normal (3–5 ng/ml) and morbidly obese (90–95 ng/ml) humans (41). Leptin (10 pmol/l–10 µmol/l) produced a concentration-dependent vasodilation in coronary arterioles isolated from Wistar rats (Fig. 2A) and mongrel dogs (Fig. 2C). Furthermore, the dilation was abolished by denudation (canine arterioles, Fig. 2D) and pretreatment with L-NAME (10 µmol/l for 30 min, Wistar rat and canine arterioles), demonstrating that leptin-mediated coronary arteriolar dilation requires the endothelium and is nitric oxide dependent. There was a significant increase in resting arteriolar tone (decrease in diameter) following L-NAME administration (from 75 ± 12 to 71 ± 12 µm; P < 0.05). Denudation was also associated with a modest increase in tone (from 101 ± 24 to 98 ± 25 µm; P = 0.272).



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 2. Leptin produced a concentration-dependent vasodilation in coronary arterioles isolated from Wistar rats that was abolished by treatment with N{omega}-nitro-L-arginine methyl ester (L-NAME) (A). Similarly, leptin produced concentration-dependent vasodilation in coronary arterioles isolated from lean Zucker rats; however, the vasodilator response was significantly attenuated in arterioles isolated from obese Zucker rats (B). Leptin also produced concentration-dependent vasodilation in coronary arterioles isolated from mongrel dogs that was markedly diminished by treatment with L-NAME (C) and by denudation with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (D). *P < 0.05 vs. baseline; {dagger}P < 0.05 vs. control (same dose).

 


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 3. Leptin did not significantly affect coronary blood flow (A), myocardial oxygen consumption (B), or mean aortic pressure (C). However, leptin (3.0 µg/min ic) did cause a significant increase in heart rate (bpm, beats/min) (D). *P < 0.05 vs. baseline. In animals pretreated with hexamethonium, leptin did not significantly affect coronary blood flow, myocardial oxygen consumption, mean aortic pressure, or heart rate. {dagger}P < 0.001, control vs. hexamethonium.

 
Leptin (10 pmol/l–10 µmol/l) also induced concentration-dependent dilation in coronary arterioles isolated from lean Zucker rats; however, the dilator response was markedly attenuated in coronary arterioles isolated from obese Zucker rats (Fig. 2B). Leptin-mediated coronary arteriolar dilation was modest at normal and obese leptin concentrations. These results demonstrate that leptin-induced endothelium-dependent coronary arteriolar dilation is predominantly a pharmacological phenomenon.

Effects of intracoronarily administered leptin on open-chest anesthetized dogs. To further examine the coronary vascular effects of leptin, we tested the effects of normal and obese concentrations of leptin on coronary blood flow and hemodynamic parameters in open-chest, anesthetized dogs. Blood gas parameters were maintained within normal physiological limits throughout the course of the experimental protocol (pH 7.37 ± 0.02; arterial PCO2, 42.3 ± 0.6 mmHg; arterial PO2, 110.7 ± 2.5 mmHg). Leptin (0.1–30.0 µg/min ic) did not significantly change coronary blood flow, myocardial oxygen consumption, or aortic pressure (Fig. 3). However, there was an uptrend in mean aortic pressure (89 ± 9–98 ± 8 mmHg) and heart rate (118 ± 12–131 ± 13 beats/min; P < 0.05) with increasing doses of leptin.

Because the coronary vasomotor effects of leptin could be masked by increased sympathetic nervous activity, we performed intracoronary leptin dose-response experiments in dogs (n = 3), pretreated with the autonomic ganglionic blocker hexamethonium (5 mg/kg iv). Although autonomic ganglionic blockade reduced myocardial oxygen consumption, coronary blood flow, heart rate, and blood pressure, the leptin dose response was unaltered in the animals treated with hexamethonium (Fig. 3). Taken together, these findings demonstrate that leptin has little effect on coronary blood flow and myocardial oxygen consumption in vivo in open-chest, anesthetized dogs. This provides further evidence that leptin-mediated coronary vasodilation is predominantly pharmacological (evident at concentrations that were not reached in the in vivo experiments).

Effects of obese hyperleptinemia on coronary endothelial function. To test the hypothesis that obese hyperleptinemia induces coronary endothelial dysfunction, we determined the effects of leptin on coronary responses to graded doses of acetylcholine (0.3–30.0 µg/min ic) and sodium nitroprusside (1.0–100.0 µg/min ic) in anesthetized, open-chest dogs (Fig. 4A) and acetylchloline (10 nmol/l–10 µmol/l) in left circumflex canine coronary rings (Fig. 4B). The fact that coronary artery disease occurs predominantly in large coronary arteries provides powerful rationale for studying the effects of hyperleptinemia on vasoreactivity in epicardial rings.



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 4. A: obese concentrations of leptin significantly attenuated coronary vasodilation to intracoronarily administered acetylcholine. *P < 0.02 vs. control (same dose). B: large concentrations of leptin significantly attenuated relaxation to acetylcholine in isolated left circumflex coronary rings. *P < 0.001 vs. control (same dose). C: physiological concentrations of leptin had no effect on relaxation to acetylcholine in isolated left circumflex coronary rings. NS, not significant. *P = 0.621.

 
In vivo, obese concentrations of leptin (81 ± 7 ng/ml, calculated coronary plasma concentration) significantly attenuated coronary dilator responses to acetylcholine (10 and 30 µg/min, Fig. 4A) but did not significantly affect coronary dilation to graded doses of sodium nitroprusside (Fig. 5). Hence, endothelium-independent coronary vasodilation was unaffected by leptin, whereas endothelium-dependent coronary vasodilation was significantly impaired. Leptin exerted no direct effect on coronary blood flow (1.19 ± 0.3 ml·min–1·g–1 before leptin infusion and 1.23 ± 0.2 ml·min–1·g–1 following 10 min of leptin infusion). Time-control experiments, in which intracoronary acetylcholine dose-response experiments were performed without leptin infusion (n = 2 dogs), revealed no changes in the coronary flow response to acetylcholine, i.e., no tachyphylaxis (data not shown).



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 5. Leptin had no significant effect on coronary vasodilation to intracoronarily administered sodium nitroprusside. P = 0.38.

 
In left circumflex coronary rings, obese concentrations of leptin (625 pmol/l or ~10 ng/ml) markedly attenuated relaxation responses to acetylcholine (6.25 nmol/l–6.25 µmol/l; Fig. 4B). Leptin (625 pmol/l) shifted the EC50 from 221 ± 56 to 507 ± 178 nmol/l (P = 0.067) and reduced the maximum effect of acetylcholine from 89.4 ± 4.8 to 69.5 ± 7.3% of maximum relaxation (P = 0.001). Physiological concentrations of leptin (250 pmol/l or ~4 ng/ml) had no effect on relaxation responses to acetylcholine (6.25 nmol/l–6.25 µmol/l; Fig. 4C). Leptin (250 pmol/l) did not significantly shift the EC50 (145 ± 80–155 ± 82 nmol/l; P = 0.251) or change the maximum effect (93.4 ± 4.5–97.6 ± 3.3% of maximum relaxation; P = 0.094) of acetylcholine (Fig. 4C). Thus obese concentrations of leptin were required to significantly attenuate relaxation responses to acetylcholine in coronary rings. Time-control experiments were also performed (n = 9 rings from 3 dogs), and there was no change in the maximal effect of acetylcholine in the absence of leptin (P = 0.34; data not shown). In summary, obese hyperleptinemia caused significant coronary endothelial dysfunction in anesthetized, open-chest dogs and in isolated, epicardial coronary rings (Fig. 4); however, leptin did not significantly alter endothelium-independent coronary vasodilation in vivo (Fig. 5).


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
A major new finding of this investigation is that ObRb is expressed in human coronary endothelium and canine left circumflex coronary arteries (Fig. 1). Furthermore, hyperleptinemia significantly impairs coronary endothelial function in vivo and in vitro, as assessed by response to muscarinic agonism (acetylcholine dose response). Additionally, we have demonstrated that pharmacological concentrations of leptin induce NO-mediated vasodilation in coronary arterioles isolated from Wistar rats, lean Zucker rats, and mongrel dogs. Notably, coronary vascular effects of leptin are consistent across species lines, i.e., leptin induces comparable vasodilator responses in arterioles from rats and dogs.

It is important to note that arteriolar vasodilation to leptin occurred at high, pharmacological concentrations of leptin (10 nmol/l–10 mmol/l, Fig. 2), i.e., little to no effect of leptin at low concentrations. Consistent with this finding, normal and obese concentrations of leptin have little, if any, effect on coronary blood flow or myocardial oxygen consumption in open-chest, anesthetized dogs (Fig. 3). Taken together, these findings may seem paradoxical in that leptin mediates endothelium-dependent vasodilation and attenuates endothelium-dependent vasodilation under the same conditions. However, careful examination of the data reveals that the leptin-induced nitric oxide-mediated dilation occurs only in vitro at concentrations well above those typically observed in morbidly obese humans. Concentrations of leptin consistent with those measured in obese humans have little to no direct effect on coronary blood flow or coronary arteriolar tone, yet leptin significantly attenuates acetylcholine-mediated vasodilation. In summary, physiological and pathophysiological (obese) concentrations of leptin have little direct effect on coronary vasomotor tone; however, obese concentrations of leptin produce significant coronary endothelial dysfunction both in vitro and in vivo.

Recent reports indicate that obese hyperleptinemia is an independent, positive risk factor for cardiovascular disease (37) and coronary artery disease (43). Moreover, leptin has been implicated in the chronic systemic inflammation associated with obesity (4). As a result, one of the major objectives of the present investigation was to test the hypothesis that hyperleptinemia causes coronary endothelial dysfunction. The findings of the present investigation demonstrate that obese concentrations of leptin cause coronary endothelial dysfunction in vivo (Figs. 4A and 5).

Coronary artery disease is chiefly a disease of conduit arteries; therefore, this hypothesis was further tested in epicardial coronary rings. Consistent with our in vivo findings, obese concentrations of leptin also caused significant coronary endothelial dysfunction in isolated left circumflex coronary rings (Fig. 4B); however, physiological concentrations of leptin did not alter coronary endothelial function (Fig. 4C). Thus obese concentrations of leptin were required to induce coronary endothelial dysfunction.

These findings are intriguing given that endothelial dysfunction is the inciting event in the pathogenesis of atherosclerosis (38). Hyperleptinemia is universal in the obese population, with plasma concentrations directly correlating with the degree of adiposity and ranging from 8 to 90 ng/ml (21, 40, 41). Additionally, obese humans are at much greater risk for cardiovascular disease (4, 11). Our findings clearly implicate leptin as a potential mediator of early endothelial dysfunction in the coronary circulation.

The precise mechanisms by which leptin induces coronary endothelial dysfunction remain unknown. Leptin has been shown to increase endothelin-1 mRNA levels and protein secretion in human umbilical vein endothelial cells (36). Thus leptin-mediated endothelin-1 production could be responsible, in part, for the observed endothelial dysfunction. However, in the present investigation, raising coronary plasma leptin concentration to levels comparable to those observed in obese humans had no significant effect on coronary blood flow (see RESULTS). Given the constrictor potency of endothelin-1, it is unlikely that increased endothelin-1 release is playing a major role in mediating the observed endothelial dysfunction. Another plausible explanation for the endothelial dysfunction is the production of reactive oxygen species. Leptin has also been shown to induce mitochondrial superoxide anion production in aortic endothelial cells via augmented fatty acid oxidation (52). Conceivably, increased superoxide production in the coronary circulation may quench nitric oxide (favor the formation of peroxynitrite) and thus reduce local nitric oxide bioavailability. The result could be attenuated dilator responses to nitric oxide-mediated agonists, e.g., acetylcholine. Also, leptin may induce proinflammatory changes in the coronary endothelium, specifically, via the production of acute phase reactants (e.g., IL-6, IL-12, and TNF-{alpha}) (27). Future studies are needed to address these issues.

Leptin receptors and coronary endothelium. Previous studies have shown that the leptin receptor is expressed in umbilical artery and vein endothelial cells (1). However, whether the leptin receptor is expressed in coronary endothelial cells has not been previously investigated. Findings from the present study demonstrate that ObRb is present in human coronary endothelium (Fig. 1). The presence of ObRb in human coronary endothelium is important in that it may provide a link by which leptin could contribute to coronary vascular tone and altered coronary vascular function in disease states, e.g., obesity and coronary artery disease (37, 43, 50). Furthermore, we recently published a partial cDNA sequence for the canine leptin receptor (accession number: AY823396). As a result, molecular studies were extended to the canine coronary circulation. The signaling-competent ObRb gene is expressed in canine left circumflex coronary arteries, thus providing a potential thoroughfare by which leptin induces coronary endothelial dysfunction. Determining the precise coronary cell type(s) that expresses the receptor requires further study. However, given that all the effects of leptin observed in the present investigation are mediated via the endothelium, we speculate that canine coronary endothelial cells express the ObRb gene. Studying ObRb protein levels in a dog is difficult. A current limitation is the lack of commercially available anti-canine leptin receptor antibodies. Antibodies raised against leptin receptors in other species (e.g., humans and mice) exhibit poor cross-reactivity with the canine receptor.

To test the hypothesis that leptin-mediated coronary arteriolar vasodilation requires the leptin receptor, we chose to use the obese Zucker rat. The obese Zucker rat carries a missense mutation in the leptin receptor gene (46), thus serving as a functional leptin receptor knockout. The lean Zucker rat has functional leptin receptors superimposed on the same genetic background as the obese Zucker rat and was used as a control. Our results suggest that leptin-mediated coronary arteriolar dilation requires the leptin receptor, because leptin caused a dose-dependent dilation in coronary arterioles isolated from lean Zucker rats but had very little effect on coronary arterioles isolated from obese Zucker rats (Fig. 2B). However, the lack of a dilator response to leptin in coronary arterioles isolated from obese Zucker rats may be due in part to endothelial dysfunction, because several earlier studies have demonstrated that obese Zucker rats show marked endothelial dysfunction in various vascular beds (7, 9, 19). In contrast, another study demonstrates that large- and intermediate-diameter cerebral arteriolar responses to endothelium-dependent vasodilator agonists are similar in lean and obese Zucker rats (2). Therefore, whether leptin mediates dilation through the leptin receptor merits future study. However, at present, there are no commercially available leptin receptor antagonists, so directly addressing this hypothesis in dogs is difficult. Because leptin acutely induces coronary endothelial dysfunction, the presence of the leptin receptor in human coronary endothelium may prove important in further elucidation of the pathophysiological changes in the coronary circulation associated with obesity.

Leptin and peripheral vascular function. Many studies have implicated leptin as a vasodilator in the peripheral vasculature in vitro (20, 26, 33, 51); however, there is controversy in the literature over the mechanisms by which leptin induces vasodilation. For example, Kimura et al.(20) found that leptin mediates nitric oxide-dependent vasodilation in rat superior mesenteric artery rings. Additionally, leptin has been shown to activate endothelial NOS in rat aortic rings (49). In contrast, Lembo et al. (26) indicate that leptin-mediated dilation of rat superior mesenteric artery rings is completely nitric oxide independent. To our knowledge, the direct effects of leptin on microvascular vasomotor responses have not been previously studied.

Leptin and coronary vascular function. Earlier studies have demonstrated that leptin is vasoactive in noncoronary vascular beds (29, 53), but the coronary vascular effects of leptin are largely uncharacterized. Again, several clinical, epidemiologic studies have shown a strong association between hyperleptinemia and risk for coronary artery disease (37, 43, 50); however, few studies to date have examined the effects of leptin on the coronary circulation. A recent study by Sundell et al. (45) found that adenosine-mediated increases in myocardial blood flow are inversely related to serum leptin concentrations in humans. The investigators concluded that leptin might play a role in the regulation of the coronary circulation in obese subjects; however, this hypothesis was not directly tested in their study. Matsuda et al. (30) examined the direct effects of subphysiological concentrations of leptin on coronary vasomotor responses in human subjects undergoing cardiac catheterization for angina (30). In their investigation, leptin induced a dose-dependent, nitric oxide-independent increase in both coronary artery diameter and coronary blood flow. However, myocardial oxygen consumption (the major determinant of coronary blood flow control) or a clinically acceptable index thereof (e.g., pressure-rate product or tension-time index) was not reported. Thus whether the leptin-mediated changes in coronary blood flow were due to alterations in myocardial metabolism was not addressed. Additionally, Matsuda et al. did not assess coronary endothelial function in their patients. It is likely that many of the subjects had coronary endothelial dysfunction, because they were being catheterized for angina. These findings are at odds with the present investigation in that leptin induced nitric oxide-dependent dilation only at high, pharmacological doses, whereas normal and obese concentrations of leptin had no effect on coronary blood flow in vivo in open-chest, anesthetized dogs (Fig. 3). It is also important to point out that leptin had little effect on myocardial oxygen consumption; i.e., leptin does not mediate metabolic coronary vasodilation (Fig. 3B). These disparate findings between the present study and Matsuda et al. (30) may be due to differences in concentration of administered leptin or species differences or both. Additionally, the subjects used in the Matsuda et al. study suffered from symptomatic coronary artery disease, whereas healthy animal subjects were used in our study.

To our knowledge, no animal studies have examined the direct effects of leptin on coronary vascular function. Although leptin did not significantly alter coronary blood flow in vivo, our data demonstrate that leptin does mediate coronary vasodilation via a nitric oxide-dependent mechanism in isolated coronary arterioles from rats and dogs, primarily at high, pharmacological leptin concentrations (>10 nmol/l) in vitro. It is crucial to recognize that the vasomotor effects of normal and obese concentrations of leptin on isolated coronary arterioles are modest, and thus it is not surprising that leptin does not alter coronary blood flow at these concentrations in vivo in open-chest, anesthetized dogs. In summary, obese concentrations of leptin do not significantly affect coronary blood flow, but they do impair coronary endothelial function.

Leptin and sympathetic nervous activity. Numerous studies have shown that leptin (administered intracerebrally or systemically) increases sympathetic nervous activity (6, 10, 13–15, 31, 34, 41, 42). It is possible that leptin-mediated activation of the sympathetic nervous system could mask leptin-dependent coronary vasodilation by way of increasing {alpha}-adrenoceptor-mediated coronary vasoconstriction (3, 47). To address this hypothesis, we performed additional intracoronary leptin dose-response experiments on open-chest, anesthetized dogs pretreated with the autonomic ganglionic blocker hexamethonium. Administration of hexamethonium decreased baseline myocardial oxygen consumption and coronary blood flow, but the leptin dose response was unaltered. Because leptin did not increase coronary blood flow in the presence of autonomic ganglionic blockade, we deduce that leptin-mediated activation of the sympathetic nervous system does not mask an endothelium-dependent vasodilator effect in vivo. As a result, we conclude that the effects of physiological and obese concentrations of leptin do not have direct coronary vasomotor effects in vivo in open-chest, anesthetized dogs.

In conclusion, our data demonstrate that signaling-competent ObRb is present in human coronary endothelium and canine coronary arteries. Furthermore, leptin induces nitric oxide-dependent vasodilation in coronary arterioles isolated from Wistar rats, lean Zucker rats, and mongrel dogs primarily at high pharmacological concentrations. In addition, normal and obese concentrations of leptin have little effect on coronary blood flow and myocardial oxygen consumption in vivo in open-chest, anesthetized dogs; therefore, physiological and pathophysiological concentrations of leptin have little direct effect on coronary-vasomotor tone. However, obese concentrations of leptin induce significant coronary endothelial dysfunction both in vivo and in vitro. This finding implicates leptin as an important mechanistic player in the initiation of atherosclerosis and accelerated progression of cardiovascular disease in obese humans.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by grants from the American Diabetes Association (to J. D. Tune) and National Heart, Lung, and Blood Institute Grant HL-67804 (to J. D. Tune).


   ACKNOWLEDGMENTS
 
We thank Alberto Araiza for expert technical assistance.


   FOOTNOTES
 

Address for reprint requests and other correspondence: J. D. Tune, Dept. of Physiology, LSU Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112-1393 (E-mail: jtune{at}lsuhsc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Akerman F, Lei ZM, and Rao CV. Human umbilical cord and fetal membranes co-express leptin and its receptor genes. Gynecol Endocrinol 16: 299–306, 2002.[Web of Science][Medline]
  2. Bohlen HG and Lash JM. Endothelium-dependent vasodilation is preserved in non-insulin-dependent Zucker fatty diabetic rats. Am J Physiol Heart Circ Physiol 268: H2366–H2374, 1995.[Abstract/Free Full Text]
  3. Chilian WM. Functional distribution of alpha 1- and alpha 2-adrenergic receptors in the coronary microcirculation. Circulation 84: 2108–2122, 1991.[Abstract/Free Full Text]
  4. Correia ML and Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 13: 215–223, 2004.[Web of Science][Medline]
  5. Corsonello A, Perticone F, Malara A, De Domenico D, Loddo S, Buemi M, Ientile R, and Corica F. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord 27: 566–573, 2003.[CrossRef][Web of Science][Medline]
  6. Dunbar JC, Hu Y, and Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 46: 2040–2043, 1997.[Abstract]
  7. Erdos B, Snipes JA, Miller AW, and Busija DW. Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C. Diabetes 53: 1352–1359, 2004.[Abstract/Free Full Text]
  8. Friedman JM and Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395: 763–770, 1998.[CrossRef][Medline]
  9. Frisbee JC and Stepp DW. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1304–H1311, 2001.[Abstract/Free Full Text]
  10. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 48: 903–908, 1999.[Abstract]
  11. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 90: 11i-21i, 2002.[Web of Science][Medline]
  12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr, and Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134–1146, 1999.[Free Full Text]
  13. Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, and Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 5: 386–392, 2003.[Web of Science][Medline]
  14. Haynes WG, Morgan DA, Walsh SA, Mark AL, and Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100: 270–278, 1997.[Web of Science][Medline]
  15. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, and Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 30: 619–623, 1997.[Abstract/Free Full Text]
  16. Hein TW, Platts SH, Waitkus-Edwards KR, Kuo L, Mousa SA, and Meininger GA. Integrin-binding peptides containing RGD produce coronary arteriolar dilation via cyclooxygenase activation. Am J Physiol Heart Circ Physiol 281: H2378–H2384, 2001.[Abstract/Free Full Text]
  17. Jones CJ, DeFily DV, Patterson JL, and Chilian WM. Endothelium-dependent relaxation competes with alpha 1- and alpha 2-adrenergic constriction in the canine epicardial coronary microcirculation. Circulation 87: 1264–1274, 1993.[Abstract/Free Full Text]
  18. Jones CJ, Kuo L, Davis MJ, DeFily DV, and Chilian WM. Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation 91: 1807–1813, 1995.[Abstract/Free Full Text]
  19. Karagiannis J, Reid JJ, Darby I, Roche P, Rand MJ, and Li CG. Impaired nitric oxide function in the basilar artery of the obese Zucker rat. J Cardiovasc Pharmacol 42: 497–505, 2003.[CrossRef][Web of Science][Medline]
  20. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M, Moriwaki C, Hano T, and Nishio I. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 273: 745–749, 2000.[CrossRef][Web of Science][Medline]
  21. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, and Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 350: 2549–2557, 2004.[Abstract/Free Full Text]
  22. Konstantinides S, Schafer K, Koschnick S, and Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 108: 1533–1540, 2001.[CrossRef][Web of Science][Medline]
  23. Konstantinides S, Schafer K, and Loskutoff DJ. The prothrombotic effects of leptinL: possible implications for the risk of cardiovascular disease in obesity. Ann NY Acad Sci 947: 134–141, 2001.[Web of Science][Medline]
  24. Kuo L, Chilian WM, and Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Physiol Heart Circ Physiol 261: H1706–H1715, 1991.[Abstract/Free Full Text]
  25. Laimer M, Ebenbichler CF, Kaser S, Sandhofer A, Weiss H, Nehoda H, Aigner F, and Patsch JR. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 26: 659–662, 2002.[CrossRef][Web of Science][Medline]
  26. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d’Amati G, and Trimarco B. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 49: 293–297, 2000.[Abstract]
  27. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, and Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 12: 57–65, 1998.[Abstract/Free Full Text]
  28. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, and Bastard JP. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28: 993–997, 2004.[CrossRef][Web of Science][Medline]
  29. Margetic S, Gazzola C, Pegg GG, and Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26: 1407–1433, 2002.[CrossRef][Web of Science][Medline]
  30. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, and Chayama K. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 26: 147–152, 2003.[CrossRef][Web of Science][Medline]
  31. Matsumura K, Abe I, Tsuchihashi T, and Fujishima M. Central effects of leptin on cardiovascular and neurohormonal responses in conscious rabbits. Am J Physiol Regul Integr Comp Physiol 278: R1314–R1320, 2000.[Abstract/Free Full Text]
  32. Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, and Mantzoros CS. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11: 1048–1054, 2003.[Web of Science][Medline]
  33. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, and Chayama K. Leptin causes vasodilation in humans. Hypertens Res 25: 161–165, 2002.[CrossRef][Web of Science][Medline]
  34. Narkiewicz K, Somers VK, Mos L, Kato M, Accurso V, and Palatini P. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertens 17: 245–249, 1999.[Web of Science][Medline]
  35. Parhami F, Tintut Y, Ballard A, Fogelman AM, and Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 88: 954–960, 2001.[Abstract/Free Full Text]
  36. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, and Wagner O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 90: 711–718, 2002.[Abstract/Free Full Text]
  37. Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol 181: 1–10, 2004.[Abstract]
  38. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801–809, 1993.[CrossRef][Medline]
  39. Schafer K, Halle M, Goeschen C, Dellas C, Pynn M, Loskutoff DJ, and Konstantinides S. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24: 112–117, 2004.[Abstract/Free Full Text]
  40. Shand BI, Scott RS, Elder PA, and George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 5: 349–353, 2003.[CrossRef][Web of Science][Medline]
  41. Shek EW, Brands MW, and Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 31: 409–414, 1998.[Abstract/Free Full Text]
  42. Shirasaka T, Takasaki M, and Kannan H. Cardiovascular effects of leptin and orexins. Am J Physiol Regul Integr Comp Physiol 284: R639–R651, 2003.[Abstract/Free Full Text]
  43. Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K, and Olsson T. Leptin is associated with increased risk of myocardial infarction. J Intern Med 246: 409–418, 1999.[CrossRef][Web of Science][Medline]
  44. Spier SA, Delp MD, Meininger CJ, Donato AJ, Ramsey MW, and Muller-Delp JM. Effects of ageing and exercise training on endothelium-dependent vasodilatation and structure of rat skeletal muscle arterioles. J Physiol 556: 947–958, 2004.[Abstract/Free Full Text]
  45. Sundell J, Huupponen R, Raitakari OT, Nuutila P, and Knuuti J. High serum leptin is associated with attenuated coronary vasoreactivity. Obes Res 11: 776–782, 2003.[Web of Science][Medline]
  46. Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, and Nakao K. Molecular cloning of rat leptin receptor isoform complementary DNAs—identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225: 75–83, 1996.[CrossRef][Web of Science][Medline]
  47. Tune JD, Gorman MW, and Feigl EO. Matching coronary blood flow to myocardial oxygen consumption. J Appl Physiol 97: 404–415, 2004.[Abstract/Free Full Text]
  48. Tune JD, Mallet RT, and Downey HF. Insulin improves contractile function during moderate ischemia in canine left ventricle. Am J Physiol Heart Circ Physiol 274: H1574–H1581, 1998.[Abstract/Free Full Text]
  49. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, Gentile MT, Fratta L, Trimarco V, Trimarco B, and Lembo G. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51: 168–173, 2002.[Abstract/Free Full Text]
  50. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, and Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104: 3052–3056, 2001.[Abstract/Free Full Text]
  51. Winters B, Mo Z, Brooks-Asplund E, Kim S, Shoukas A, Li D, Nyhan D, and Berkowitz DE. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lepob) mice. J Appl Physiol 89: 2382–2390, 2000.[Abstract/Free Full Text]
  52. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, and Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276: 25096–25100, 2001.[Abstract/Free Full Text]
  53. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, and Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett 546: 45–50, 2003.[CrossRef][Web of Science][Medline]
  54. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425–432, 1994.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. A. Payne, H. G. Bohlen, U. D. Dincer, L. Borbouse, and J. D. Tune
Periadventitial adipose tissue impairs coronary endothelial function via PKC-{beta}-dependent phosphorylation of nitric oxide synthase
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H460 - H465.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
J. Malyszko, J.S. Malyszko, P. Kozminski, K. Pawlak, and M. Mysliwiec
Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule
Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 338 - 345.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. K. Surmi, R. D. Atkinson, M. L. Gruen, K. R. Coenen, and A. H. Hasty
The role of macrophage leptin receptor in aortic root lesion formation
Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E488 - E495.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. F. Bodary
Links Between Adipose Tissue and Thrombosis in the Mouse
Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2284 - 2291.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. D. Knudson, G. M. Dick, and J. D. Tune
Adipokines and Coronary Vasomotor Dysfunction
Experimental Biology and Medicine, June 1, 2007; 232(6): 727 - 736.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
S. Musaad and E. N. Haynes
Biomarkers of Obesity and Subsequent Cardiovascular Events
Epidemiol. Rev., May 10, 2007; (2007) mxm005v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. M. Dick, P. S. Katz, M. Farias III, M. Morris, J. James, J. D. Knudson, and J. D. Tune
Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2997 - H3002.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Nishio, M. Sakurai, T. Kusuyama, M. Shigemitsu, T. Fukui, K. Kawamura, S. Itoh, N. Konno, and T. Katagiri
A Randomized Comparison of Pioglitazone to Inhibit Restenosis After Coronary Stenting in Patients With Type 2 Diabetes
Diabetes Care, January 1, 2006; 29(1): 101 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. Knudson, U. D. Dincer, G. M. Dick, H. Shibata, R. Akahane, M. Saito, and J. D. Tune
Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1038 - H1046.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/1/H48    most recent
01159.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knudson, J. D.
Right arrow Articles by Tune, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knudson, J. D.
Right arrow Articles by Tune, J. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.